Aclaris Therapeutics sells 5.7M shares for $20M gross proceeds in ATM offering

Aclaris Therapeutics, Inc.

5.7M shares sold on March 10, 2026 for aggregate gross proceeds of $20.0M.
Purchasers include Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP.
Sale under amended sales agreement with Leerink Partners and Cantor Fitzgerald dated Feb 27, 2025.
Gross proceeds of $20M implies average price per share of approximately $3.51.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.